Physician profile

Paul H Moore

Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) · Jackson, MS

NPI 1962679241

$8,599.27

in general payments reported to CMS, 2019-2025

32 companies · $459 in 2025

The $459 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).

See the full distribution for Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology)

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,354.47
Travel and Lodging$1,301.09
Education$1,000.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $3,939.73 2022-2023 Da Vinci Surgical System, Davinci Xi
Medtronic, INC. $1,316.86 2022-2025 Interstim
Axonics, INC. $887.86 2020-2024 Axonics
Allergan, INC. $433.06 2019-2021
Abbvie INC. $383.80 2019-2024
Sumitomo Pharma America, INC. $206.75 2023-2025 Gemtesa, Orgovyx
Astellas Pharma US INC $196.78 2019-2024 Xtandi
Boston Scientific Corporation $141.50 2021-2025 Axonics, Solyx Sis System
Urovant Sciences INC $137.72 2021-2022
Davol INC. $136.75 2022-2024 Arista Ah Flexitip
Caldera Medical, INC $127.00 2021-2023 Desara
Procept Biorobotics Corporation $87.15 2024 Aquabeam System
Coloplast Corp $77.54 2020-2025
Urogen Pharma, INC. $65.28 2025
Bayer Healthcare Pharmaceuticals INC. $61.81 2025
Show all 31 companies
CompanyGeneral paymentsYearsTop products
Abbott Laboratories $50.06 2021
Applied Medical Resources Corporation $42.83 2023
Ferring Pharmaceuticals INC. $39.41 2024-2025 Adstiladrin
Steris Corporation $32.90 2024
Laborie Medical Technologies Corp. $27.92 2024 Urgent PC Neuromodulation System
Tempus Ai, INC $24.97 2025 Xt Cdx
Merck Sharp & Dohme LLC $21.78 2025 Keytruda, Keytruda Qlex
Dendreon Pharmaceuticals LLC $20.00 2024 Provenge
Eisai INC. $19.98 2022
Hollister Incorporated $18.58 2024
Abc Home Medical Supply, INC. $18.58 2024
Pfizer INC. $18.57 2024
Medtronic USA, INC. $17.74 2020
Progenics Pharmaceuticals, INC. $17.29 2024
Mission Pharmacal Company $16.35 2024 Uribel Tabs
Exeltis, USA INC. $12.72 2022

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$9,004.32 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Paul H Moore

$8,599.27

in general payments reported 2019-2025

Years
2019-2025
Top company
Gynesonics, INC.
Context
The $459 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).

https://glasscript.com/doctor/180353/paul-h-moore

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.